Written by
Share article:
Earlier this year, Pro Medicus announced its $5 million investment into Elucid, a Boston based AI vendor specialising in AI for cardiac CT. The investment was made as part of Elucid’s Series C funding round, which was led by Elevage Medical Technologies and raised $80 million, bringing the company’s total funding to $121 million.
Dr Sam Hupert, Pro Medicus’s CEO, stated that the company anticipates substantial growth in AI for cardiac CT, and noted that there is material reimbursement for the two products that Elucid intends to bring to market. Through the investment, Pro Medicus will partner with Elucid to integrate its FFR-CT and plaque characterisation AI solutions into Visage, a subsidiary of Pro Medicus.
This partnership through investment is both indicative of Visage’s evolving strategy and the shifting dynamics in the AI funding landscape.
